Other challenges of PI3K/Akt/mTOR-targeted therapy include drug-related adverse events and/or direct-drug toxicity, such as hyperglycemia, diarrhea, nausea, vomiting, cutaneous reactions, hypertension, hepatotoxic effects, and neuropsychiatric problems [41,141]. This evidence concerns the gene PIK3CA and hypertensive disorder.